0001213900-23-048185.txt : 20230612 0001213900-23-048185.hdr.sgml : 20230612 20230612164220 ACCESSION NUMBER: 0001213900-23-048185 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230612 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230612 DATE AS OF CHANGE: 20230612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthwell Acquisition Corp. I CENTRAL INDEX KEY: 0001845013 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 861911840 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40697 FILM NUMBER: 231008705 BUSINESS ADDRESS: STREET 1: 1001 GREEN BAY RD. #227 CITY: WINNETKA STATE: IL ZIP: 60093 BUSINESS PHONE: 847-612-3359 MAIL ADDRESS: STREET 1: 1001 GREEN BAY RD. #227 CITY: WINNETKA STATE: IL ZIP: 60093 8-K 1 ea180165-8k425_health1.htm CURRENT REPORT
0001845013 false 0001845013 2023-06-12 2023-06-12 0001845013 HWEL:UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemableWarrantMember 2023-06-12 2023-06-12 0001845013 HWEL:ClassCommonStockParValue0.0001PerShareMember 2023-06-12 2023-06-12 0001845013 HWEL:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassCommonStockFor11.50PerShareMember 2023-06-12 2023-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 12, 2023

 

 

 

Healthwell Acquisition Corp. I

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40697   86-1911840
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

1001 Green Bay Rd, #227

Winnetka, IL 60093

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (847) 230-9162

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange
on which registered
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant   HWELU   The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   HWEL   The Nasdaq Stock Market LLC
Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share   HWELW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

As previously disclosed by Healthwell Acquisition Corp. I, a Delaware corporation (“Healthwell”), in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 3, 2023, Healthwell entered into a business combination agreement on April 27, 2023 (as amended on May 15, 2023 and as may be further amended or supplemented from time to time, “Business Combination Agreement”) with Starton Therapeutics, Inc., a British Columbia corporation (“Starton”), HWEL Holdings Corp., a Delaware corporation and wholly-owned subsidiary of Healthwell (“Pubco”), HWEL Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of Pubco, 1412384 B.C. Unlimited Liability Company, a British Columbia unlimited liability company and wholly-owned subsidiary of Pubco (“CallCo”), 1412388 B.C. Ltd, a British Columbia corporation and wholly-owned subsidiary of CallCo, Healthwell Acquisition Corp. I Sponsor LLC, a Delaware limited liability company, as the representative from and after the Effective Time (as defined in the Business Combination Agreement) of the stockholders of Pubco (other than the Starton Shareholders (as defined below) and their successors and assignees), and Kiriakos Charlie Perperidis, in the capacity as the representative of the shareholders of Starton (the “Starton Shareholders”) from and after the Effective Time (all of the transactions contemplated by the Business Combination Agreement, including the issuances of securities thereunder, the “Transaction”).

 

On June 12, 2023, Starton issued a press release announcing updates on Starton’s Phase 1b STAR-LLD clinical trial of its investigational continuous delivery lenalidomide in multiple myeloma, including that the U.S. Food and Drug Administration has notified Starton that it may proceed with the U.S.-based program in second-line transplant-ineligible patients using the combination of STAR-LLD, Velcade®, and dexamethasone (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”).

 

The information in this Item 7.01 of this Current Report and the Press Release being furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the Press Release shall not be incorporated by reference into any filing with the SEC whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Additional Information and Where to Find It

 

In connection with the Transaction, Pubco filed a registration statement on Form S-4 with the SEC on May 15, 2023 (as may be amended or supplemented from time to time, the “Registration Statement”), which includes a preliminary proxy statement and a prospectus in connection with the Transaction. STOCKHOLDERS OF HEALTHWELL ARE ADVISED TO READ THE PRELIMINARY PROXY STATEMENT AND, WHEN AVAILABLE, ANY AMENDMENTS THERETO, THE DEFINITIVE PROXY STATEMENT, THE PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. THIS DOCUMENT WILL NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE TRANSACTION. IT IS ALSO NOT INTENDED TO FORM THE BASIS OF ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF THE TRANSACTION. When available, the definitive proxy statement and other relevant documents will be mailed to the stockholders of Healthwell as of a record date to be established for voting on the Transaction. Stockholders and other interested persons will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, the Registration Statement and other documents filed the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov.

 

Healthwell’s stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Healthwell Acquisition Corp. I, 1001 Green Bay Rd, #227 Winnetka, IL 60093; e-mail: healthwell.management@healthwellspac.com.

 

1

 

 

Forward-Looking Statements

 

This Current Report contains forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding Starton and the Transaction and the future held by the respective management teams of Healthwell or Starton, the anticipated benefits and the anticipated timing of the Transaction, future financial condition and performance of Starton and expected financial impacts of the Transaction (including future revenue, pro forma enterprise value and cash balance), the satisfaction of closing conditions to the Transaction, financing transactions, if any, related to the Transaction, the level of redemptions of Healthwell’s public stockholders and the products and markets and expected future performance and market opportunities of Starton. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “may,” “might,” “strategy,” “opportunity,” “plan,” “project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including, without limitation: (i) the risk that the Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Healthwell’s securities; (ii) the risk that the Transaction may not be completed by Healthwell’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Healthwell; (iii) the failure to satisfy the conditions to the consummation of the Transaction, including, among others, the condition that Healthwell has cash or cash equivalents of at least $15 million, and the requirement that the Business Combination Agreement and the transactions contemplated thereby be approved by the stockholders of each of Healthwell and Starton; (iv) the failure to obtain any applicable regulatory approvals required to consummate the Transaction; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement; (vi) the effect of the announcement or pendency of the Transaction on Starton’s business relationships, operating results, and business generally; (vii) risks that the Transaction disrupts current plans and operations of Starton; (viii) the risk that Pubco may not be able to raise funds in a PIPE financing or may not be able to raise as much as anticipated; (ix) the outcome of any legal proceedings that may be instituted against Starton or Healthwell related to the Business Combination Agreement or the Transaction; (x) the ability to maintain the listing of Healthwell’s securities on a national securities exchange or failure of Pubco to meet initial listing standards in connection with the consummation of the Transaction; (xi) uncertainty regarding outcomes of Starton’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates; (xii) risks associated with Starton’s efforts to commercialize a product candidate; (xiii) Starton’s ability to negotiate and enter into definitive agreements for supply, sales, marketing, and/or distribution on favorable terms, if at all; (xiv) the impact of competing product candidates on Starton’s business; (xv) intellectual property-related claims; and (xvi) Starton’s ability to attract and retain qualified personnel; and (xvii) Starton’s ability to continue to source the raw materials for its product candidates.

 

The foregoing list of factors is not exhaustive. Recipients should carefully consider such factors and the other risks and uncertainties described and to be described in the “Risk Factors” section of Healthwell’s initial public offering (the “IPO”) prospectus filed with the SEC on August 4, 2021, Healthwell’s Annual Report on Form 10-K filed for the year ended December 31, 2022 filed with the SEC on March 3, 2023 and subsequent periodic reports filed by Healthwell with the SEC, the Registration Statement and other documents filed or to be filed by Healthwell and Pubco from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Recipients are cautioned not to put undue reliance on forward-looking statements, and neither Starton, Healthwell nor Pubco assume any obligation to, nor intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Neither Starton, Healthwell nor Pubco gives any assurance that either Starton or Healthwell, or the combined company, will achieve its expectations.

 

2

 

 

Information Sources; No Representations

 

The communication furnished herewith has been prepared for use by Healthwell and Starton in connection with the Transaction. The information therein does not purport to be all-inclusive. The information therein is derived from various internal and external sources, with all information relating to the business, past performance, results of operations and financial condition of Healthwell derived entirely from Healthwell and all information relating to the business, past performance, results of operations and financial condition of Starton derived entirely from Starton. No representation is made as to the reasonableness of the assumptions made with respect to the information therein, or to the accuracy or completeness of any projections or modeling or any other information contained therein. Any data on past performance or modeling contained therein is not an indication as to future performance.

  

No representations or warranties, express or implied, are given in respect of the communication. To the fullest extent permitted by law in no circumstances will Healthwell, Starton or Pubco, or any of their respective subsidiaries, affiliates, shareholders, representatives, partners, directors, officers, employees, advisors or agents, be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this communication (including without limitation any projections or models), any omissions, reliance on information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith, which information relating in any way to the operations of Starton has been derived, directly or indirectly, exclusively from Starton and has not been independently verified by Healthwell. Neither the independent auditors of Healthwell nor the independent auditors of or Starton audited, reviewed, compiled or performed any procedures with respect to any projections or models for the purpose of their inclusion in the communication and, accordingly, neither of them expressed any opinion or provided any other form of assurances with respect thereto for the purposes of the communication.

 

Prior Disclosures

 

Starton is aware that its CEO appeared on the television program “Unicorn Hunters” on June 7, 2021. During that appearance, the CEO made a number of representations as to Starton’s approach to reformulating drug products to improve efficacy, tolerability and patients’ quality of life. As part of these representations, the CEO raised the specific example of Starton’s investigational reformulation of Revlimid™. While Starton believes in the value of its product, it understands that any clinical superiority claims cannot be made absent specific findings from rigorous clinical studies which Starton has not undertaken. The CEO’s comments on the television program were not intended to suggest Starton has conducted such studies; Starton does not have data to support these specific representations and disclaims any representations or purported representations by its CEO which either stated or implied the contrary.

 

Trademarks and Tradenames

 

This communication includes trademarks of Starton, which are protected under applicable intellectual property laws and are the property of Starton or its subsidiaries. This communication also includes other trademarks, trade names and service marks that are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

 

3

 

 

Participants in the Solicitation

 

Healthwell, Starton, Pubco and their respective directors and executive officers may be deemed participants in the solicitation of proxies of Healthwell’s stockholders in connection with the Transaction. Healthwell’s stockholders and other interested persons may obtain more detailed information regarding the names, affiliations, and interests of certain of Healthwell executive officers and directors in the solicitation by reading Healthwell’s final prospectus filed with the SEC on August 4, 2021 in connection with the IPO, Healthwell’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 3, 2023 and Healthwell’s other filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the Transaction, which may, in some cases, be different from those of stockholders generally, are set forth in the Registration Statement relating to the Transaction. These documents can be obtained free of charge from the source indicated above.

 

No Offer or Solicitation

 

This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated June 12, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 12, 2023 Healthwell Acquisition Corp. I
       
  By: /s/ Alyssa Rapp
    Name:  Alyssa Rapp
    Title: Chief Executive Officer

 

 

5

 

 

 

 EX-99.1 2 ea180165ex99-1_health1.htm PRESS RELEASE, DATED JUNE 12, 2023

Exhibit 99.1

 

 

 

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

 

·FDA agrees to the planned Phase 1b study in second-line transplant ineligible patients in multiple myeloma
   
·Treatment regimen will include Velcade® (bortezomib) and dexamethasone and replace oral Revlimid® with STAR-LLD

 

PARAMUS, N.J., June 12, 2023 – Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today provided updates on its Phase 1b STAR-LLD clinical trial of its investigational continuous delivery lenalidomide in multiple myeloma.

 

The U.S. Food and Drug Administration (“FDA”) notified the Company that it may proceed with the U.S.-based program in second-line transplant-ineligible patients using the combination of STAR-LLD, Velcade, and dexamethasone. This treatment paradigm will replace oral Revlimid with STAR-LLD. The planned study that follows this development will evaluate six patients for tolerability, immune biomarkers, and signals of efficacy of continuously delivered lenalidomide at the highest planned daily dose. The study is expected to accrue six patients in the United States in three to four centers over a period of 10 months and will provide readouts in the tolerability of the regimen, the impact of continuous delivery on immune function by measuring biomarkers of T-cell, NK-cell, and B-cell upregulation, and cytokine production induced by lenalidomide. It will also provide signals of efficacy in assessing response rates, duration of response, progression free survival, and changes in minimal residual disease.

 

Pedro Lichtinger, Chairman and CEO of Starton Therapeutics commented, “Today’s announcement marks a significant development for Starton and patients in need of approved drugs and an improved quality of life, and we are excited to begin this critical program in transplant-ineligible patients with multiple myeloma. This study will provide initial evidence of the impact of continuous delivery of lenalidomide both in terms of safety and efficacy, as well as provide clarity for signals of improvement in patients outcomes.”

 

As part of the development plans, the FDA agreed to have a meeting to review the initial data on safety and activity from the study as an interim analysis, while patients continue treatment for efficacy endpoints. This interim review is aimed at helping develop the plans for the approval path forward with Phase 2 studies for multiple myeloma, as well as other malignancies where lenalidomide has shown activity but is not approved for the new indications planned for study.

 

Dr. Jamie Oliver, Starton’s Chief Medical Officer noted, “We are very happy with the agreed protocol, which allows a quick read for the key safety and efficacy data which we will review with the FDA. The upcoming Phase 1b clinical study in multiple myeloma is on track to begin enrollment in Q4 2023. Treatment of second-line patients at our proposed optimal dose of continuous lenalidomide in combination with the proteasome inhibitor Velcade and dexamethasone allows us to demonstrate activity in an established standard of care regimen by replacing Revlimid with STAR-LLD.”

 

Starton has signed an agreement for a business combination with Healthwell Acquisition Corp. I (Nasdaq: HWEL) (“Healthwell”). Please see “Additional Information and Where to Find It” below for additional information related to the proposed business combination.

 

 

 

About STAR-LLD

 

STAR-LLD is a continuous delivery lenalidomide in development to expand and replace the standard of care for the most common blood cancers, multiple myeloma and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide and shrank by 80% with STAR-LLD. The study also showed 100% efficacy (overall response rate ORR) at 144 mcg/day continuous LLD and 20% tumor elimination vs. 0% ORR with active control with daily pulsatile once daily dosing. In addition, a Phase 1 bioavailability study in healthy men comparing STAR-LLD to Revlimid demonstrated the drug is well tolerated and is >93% bioavailable by the subcutaneous route. It was also observed that the Cmax is <90% lower than oral Revlimid. These data support the safety of the planned Phase 1 dose of 400 mcg/hr (9.6 mg a day) versus a standard 25 mg a day dose for Revlimid.

 

About Starton Therapeutics

 

A clinical-stage biotechnology platform company focused on transforming standard of care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton’s proprietary transdermal technology is intended to increase efficacy of approved drugs, to make them more tolerable and expand their potential use. To learn more, visit www.startontx.com.

 

About Healthwell

 

Healthwell is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

 

Additional Information and Where to Find It

 

In connection with the transactions contemplated by the business combination agreement, dated April 27, 2023 (as amended on May 15, 2023 and as many be further amended or supplemented from time to time, the “Business Combination Agreement,” and all of the transactions contemplated thereunder, the “Transaction”), by and among Starton, Healthwell, HWEL Holdings Corp., a Delaware corporation and wholly-owned subsidiary of Healthwell (“Pubco”), and other parties thereto, Pubco filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2023 (as may be amended or supplemented from time to time, the “Registration Statement”), which includes a preliminary proxy statement and a prospectus in connection with the Transaction. STOCKHOLDERS OF HEALTHWELL ARE ADVISED TO READ THE PRELIMINARY PROXY STATEMENT, AND, WHEN AVAILABLE, ANY AMENDMENTS THERETO, THE DEFINITIVE PROXY STATEMENT, THE PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. THIS DOCUMENT WILL NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE TRANSACTION. IT IS ALSO NOT INTENDED TO FORM THE BASIS OF ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF THE TRANSACTION. When available, the definitive proxy statement and other relevant documents will be mailed to the stockholders of Healthwell as of a record date to be established for voting on the Transaction. Stockholders and other interested persons will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, the Registration Statement and other documents filed the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov. Healthwell’s stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Healthwell Acquisition Corp., 1001 Green Bay Rd, #227 Winnetka, IL 60093; e-mail: healthwell.management@healthwellspac.com.

 

2

 

 

Forward-Looking Statements

 

This communication contains forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding Starton and the Transaction and the future held by the respective management teams of Healthwell or Starton, the anticipated benefits and the anticipated timing of the Transaction, future financial condition and performance of Starton and expected financial impacts of the Transaction (including future revenue, pro forma enterprise value and cash balance), the satisfaction of closing conditions to the Transaction, financing transactions, if any, related to the Transaction, the level of redemptions of Healthwell’s public stockholders and the products and markets and expected future performance and market opportunities of Starton. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “may,” “might,” “strategy,” “opportunity,” “plan,” “project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including, without limitation: (i) the risk that the Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Healthwell’s securities; (ii) the risk that the Transaction may not be completed by Healthwell’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Healthwell; (iii) the failure to satisfy the conditions to the consummation of the Transaction, including, among others, the condition that Healthwell has cash or cash equivalents of at least $15 million, and the requirement that the Business Combination Agreement and the transactions contemplated thereby be approved by the stockholders of each of Healthwell and Starton; (iv) the failure to obtain any applicable regulatory approvals required to consummate the Transaction; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vi) the effect of the announcement or pendency of the Transaction on Starton’s business relationships, operating results, and business generally; (vii) risks that the Transaction disrupts current plans and operations of Starton; (viii) the risk that Pubco may not be able to raise funds in a PIPE financing or may not be able to raise as much as anticipated; (ix) the outcome of any legal proceedings that may be instituted against Starton or Healthwell related to the Business Combination Agreement or the Transaction; (x) the ability to maintain the listing of Healthwell’s securities on a national securities exchange or failure of Pubco to meet initial listing standards in connection with the consummation of the Transaction; (xi) uncertainty regarding outcomes of Starton’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates; (xii) risks associated with Starton’s efforts to commercialize a product candidate; (xiii) Starton’s ability to negotiate and enter into definitive agreements for supply, sales, marketing, and/or distribution on favorable terms, if at all; (xiv) the impact of competing product candidates on Starton’s business; (xv) intellectual property-related claims; and (xvi) Starton’s ability to attract and retain qualified personnel; and (xvii) Starton’s ability to continue to source the raw materials for its product candidates.

 

The foregoing list of factors is not exhaustive. Recipients should carefully consider such factors and the other risks and uncertainties described and to be described in the “Risk Factors” section of Healthwell’s initial public offering (the “IPO”) prospectus filed with the SEC on August 4, 2021, Healthwell’s Annual Report on Form 10-K filed for the year ended December 31, 2022 filed with the SEC on March 3, 2023 and subsequent periodic reports filed by Healthwell with the SEC, the Registration Statement and other documents filed or to be filed by Healthwell and Pubco from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Recipients are cautioned not to put undue reliance on forward-looking statements, and neither Starton, Healthwell nor Pubco assume any obligation to, nor intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Neither Starton, Healthwell nor Pubco gives any assurance that either Starton or Healthwell, or the combined company, will achieve its expectations.

 

3

 

 

Information Sources; No Representations

 

The information herein does not purport to be all-inclusive. The information herein is derived from various internal and external sources, with all information relating to the business, past performance, results of operations and financial condition of Healthwell derived entirely from Healthwell and all information relating to the business, past performance, results of operations and financial condition of Starton derived entirely from Starton. No representation is made as to the reasonableness of the assumptions made with respect to the information therein, or to the accuracy or completeness of any projections or modeling or any other information contained therein. Any data on past performance or modeling contained therein is not an indication as to future performance.

 

No representations or warranties, express or implied, are given in respect of the communication. To the fullest extent permitted by law in no circumstances will Healthwell, Starton or Pubco, or any of their respective subsidiaries, affiliates, shareholders, representatives, partners, directors, officers, employees, advisors or agents, be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this communication (including without limitation any projections or models), any omissions, reliance on information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith, which information relating in any way to the operations of Starton has been derived, directly or indirectly, exclusively from Starton and has not been independently verified by Healthwell. Neither the independent auditors of Healthwell nor the independent auditors of or Starton audited, reviewed, compiled or performed any procedures with respect to any projections or models for the purpose of their inclusion in the communication and, accordingly, neither of them expressed any opinion or provided any other form of assurances with respect thereto for the purposes of the communication.

 

Prior Disclosures

 

Starton is aware that its CEO appeared on the television program “Unicorn Hunters” on June 7, 2021. During that appearance, the CEO made a number of representations as to Starton’s approach to reformulating drug products to improve efficacy, tolerability and patients’ quality of life. As part of these representations, the CEO raised the specific example of Starton’s investigational reformulation of Revlimid. While Starton believes in the value of its product, it understands that any clinical superiority claims cannot be made absent specific findings from rigorous clinical studies which Starton has not undertaken. The CEO’s comments on the television program were not intended to suggest Starton has conducted such studies; Starton does not have data to support these specific representations and disclaims any representations or purported representations by its CEO which either stated or implied the contrary.

 

Trademarks and Tradenames

 

This communication includes trademarks of Starton, which are protected under applicable intellectual property laws and are the property of Starton or its subsidiaries. This communication also includes other trademarks, trade names and service marks that are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

 

Participants in the Solicitation

 

Healthwell, Starton, Pubco and their respective directors and executive officers may be deemed participants in the solicitation of proxies of Healthwell’s stockholders in connection with the Transaction. Healthwell’s stockholders and other interested persons may obtain more detailed information regarding the names, affiliations, and interests of certain of Healthwell executive officers and directors in the solicitation by reading Healthwell’s final prospectus filed with the SEC on August 4, 2021 in connection with the IPO, Healthwell’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 3, 2023 and Healthwell’s other filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the Transaction, which may, in some cases, be different from those of stockholders generally, are set forth in the Registration Statement relating to the Transaction. These documents can be obtained free of charge from the source indicated above.

 

4

 

 

No Offer or Solicitation

 

This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

 

Contacts

 

Starton Therapeutics

Investors@startontx.com

 

Healthwell

HealthwellSPAC@edelman.com

 

 

5

 

 

 EX-101.SCH 3 hwel-20230612.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 hwel-20230612_def.xml XBRL DEFINITION FILE EX-101.LAB 5 hwel-20230612_lab.xml XBRL LABEL FILE Class of Stock [Axis] Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant Class A common stock, par value $0.0001 per share Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 hwel-20230612_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 12, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 12, 2023
Entity File Number 001-40697
Entity Registrant Name Healthwell Acquisition Corp. I
Entity Central Index Key 0001845013
Entity Tax Identification Number 86-1911840
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1001 Green Bay Rd
Entity Address, Address Line Two #227
Entity Address, City or Town Winnetka
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60093
City Area Code 847
Local Phone Number 230-9162
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant  
Title of 12(b) Security Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant
Trading Symbol HWELU
Security Exchange Name NASDAQ
Class A common stock, par value $0.0001 per share  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol HWEL
Security Exchange Name NASDAQ
Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share  
Title of 12(b) Security Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share
Trading Symbol HWELW
Security Exchange Name NASDAQ
XML 9 ea180165-8k425_health1_htm.xml IDEA: XBRL DOCUMENT 0001845013 2023-06-12 2023-06-12 0001845013 HWEL:UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemableWarrantMember 2023-06-12 2023-06-12 0001845013 HWEL:ClassCommonStockParValue0.0001PerShareMember 2023-06-12 2023-06-12 0001845013 HWEL:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassCommonStockFor11.50PerShareMember 2023-06-12 2023-06-12 iso4217:USD shares iso4217:USD shares 0001845013 false 8-K 2023-06-12 Healthwell Acquisition Corp. I DE 001-40697 86-1911840 1001 Green Bay Rd #227 Winnetka IL 60093 847 230-9162 true false false false Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant HWELU NASDAQ Class A common stock, par value $0.0001 per share HWEL NASDAQ Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share HWELW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://healthwellspac.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea180165-8k425_health1.htm ea180165ex99-1_health1.htm hwel-20230612.xsd hwel-20230612_def.xml hwel-20230612_lab.xml hwel-20230612_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea180165-8k425_health1.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "hwel-20230612_def.xml" ] }, "inline": { "local": [ "ea180165-8k425_health1.htm" ] }, "labelLink": { "local": [ "hwel-20230612_lab.xml" ] }, "presentationLink": { "local": [ "hwel-20230612_pre.xml" ] }, "schema": { "local": [ "hwel-20230612.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 3, "memberStandard": 0, "nsprefix": "HWEL", "nsuri": "http://healthwellspac.com/20230612", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea180165-8k425_health1.htm", "contextRef": "From2023-06-12to2023-06-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://healthwellspac.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea180165-8k425_health1.htm", "contextRef": "From2023-06-12to2023-06-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "HWEL_ClassCommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A common stock, par value $0.0001 per share" } } }, "localname": "ClassCommonStockParValue0.0001PerShareMember", "nsuri": "http://healthwellspac.com/20230612", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "domainItemType" }, "HWEL_RedeemableWarrantsEachWarrantExercisableForOneShareOfClassCommonStockFor11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share" } } }, "localname": "RedeemableWarrantsEachWarrantExercisableForOneShareOfClassCommonStockFor11.50PerShareMember", "nsuri": "http://healthwellspac.com/20230612", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "domainItemType" }, "HWEL_UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemableWarrantMember", "nsuri": "http://healthwellspac.com/20230612", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthwellspac.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001213900-23-048185-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-048185-xbrl.zip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end